The Asthma Control Questionnaire as a clinical trial endpoint: Past experience and recommendations for future use

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 69, Issue 9, 2014, Pages 1119-1140

  Barnes, P J ^a   Casale, T B ^b   Dahl, R ^c   Pavord, I D ^d   Wechsler, M E ^e  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e DEPARTMENT OF MEDICINE   (United States)

Author keywords

asthma; Asthma Control Questionnaire; clinical trials; endpoints

Indexed keywords

ASTHMA; BIOASSAY; CLINICAL TRIAL (TOPIC); HUMAN; PROCEDURES; QUESTIONNAIRE; STANDARDS; TREATMENT OUTCOME;

ASTHMA; CLINICAL TRIALS AS TOPIC; ENDPOINT DETERMINATION; HUMANS; SURVEYS AND QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 84905823563     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/all.12415     Document Type: Article

References (139)

1. GINA. Global strategy for asthma management and prevention. 2012. Available from: http://www.ginasthma.org/Guidelineitem.asp. Last accessed 10 January 2014.
2. Rabe KF, Adachi M, Lai CK, Soriano JB, Vermeire PA, Weiss KB, et al. Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. J Allergy Clin Immunol 2004; 114: 40-47.
3. Chapman KR, Boulet LP, Rea RM, Franssen E,. Suboptimal asthma control: prevalence, detection and consequences in general practice. Eur Respir J 2008; 31: 320-325.
4. Williams SA, Wagner S, Kannan H, Bolge SC,. The association between asthma control and health care utilization, work productivity loss and health-related quality of life. J Occup Environ Med 2009; 51: 780-785.
5. Reddel HK, Taylor DR, Bateman ED, Boulet LP, Boushey HA, Busse WW, et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 2009; 180: 59-99.
6. National Heart, Lung and Blood Institute. National Asthma Education and Prevention Program Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. Bethesda, MD: National Institutes of Health, 2007.
7. Chen H, Gould MK, Blanc PD, Miller DP, Kamath TV, Lee JH, et al. Asthma control, severity, and quality of life: quantifying the effect of uncontrolled disease. J Allergy Clin Immunol 2007; 120: 396-402.
8. Chen H, Blanc PD, Hayden ML, Bleecker ER, Chawla A, Lee JH, et al. Assessing productivity loss and activity impairment in severe or difficult-to-treat asthma. Value Health 2008; 11: 231-239.
9. Sullivan SD, Rasouliyan L, Russo PA, Kamath T, Chipps BE, TENOR Study Group. Extent, patterns, and burden of uncontrolled disease in severe or difficult-to-treat asthma. Allergy 2007; 62: 126-133.
10. Magnan A,. Tools to assess (and achieve?) long-term asthma control. Respir Med 2004; 98 (Suppl B): S16-S21.
11. Juniper EF, Wisniewski ME, Cox FM, Emmett AH, Nielsen KE, O'Byrne PM,. Relationship between quality of life and clinical status in asthma: a factor analysis. Eur Respir J 2004; 23: 287-291.
12. Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ, Pauwels RA, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 2004; 170: 836-844.
13. Pearson MG, Bucknall CE, editors. Measuring clinical outcomes in asthma: a patient-focused approach. London: Royal College of Physicians; 1999.
14. Baylor Health Care System. Rules of Two®. 2011. Available from: http://www.baylorhealth.com/PhysiciansLocations/Dallas/SpecialtiesServices/ Asthma/Pages/RulesofTwo.aspx. Last accessed 15 October 2013.
15. Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, King DR,. Development and validation of a questionnaire to measure asthma control. Eur Respir J 1999; 14: 902-907.
16. Juniper EF,. Asthma control questionnaire: background, administration and analysis. Bosham: QOL Technologies, 2004.
17. Nathan RA, Sorkness CA, Kosinski M, Schatz M, Li JT, Marcus P, et al. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol 2004; 113: 59-65.
18. LeBlanc A, Robichaud P, Lacasse Y, Boulet LP,. Quantification of asthma control: validation of the Asthma Control Scoring System. Allergy 2007; 62: 120-125.
19. Vollmer WM, Markson LE, O'Connor E, Sanocki LL, Fitterman L, Berger M, et al. Association of asthma control with health care utilization and quality of life. Am J Respir Crit Care Med 1999; 160: 1647-1652.
20. Ahmed S, Ernst P, Tamblyn R, Colman N,. Validation of The 30 Second Asthma Test(TM) as a measure of asthma control. Can Respir J 2007; 14: 105-109.
21. Lara M, Sherbourne C, Duan N, Morales L, Gergen P, Brook RH,. An English and Spanish Pediatric Asthma Symptom Scale. Med Care 2000; 38: 342-350.
22. Halbert RJ, Tinkelman DG, Globe DR, Lin SL,. Measuring asthma control is the first step to patient management: a literature review. J Asthma 2009; 46: 659-664.
23. O'Byrne PM, Reddel HK, Eriksson G, Ostlund O, Peterson S, Sears MR, et al. Measuring asthma control: a comparison of three classification systems. Eur Respir J 2010; 36: 269-276.
24. Juniper EF, Gruffydd-Jones K, Ward S, Svensson K,. Asthma Control Questionnaire in children: validation, measurement properties, interpretation. Eur Respir J 2010; 36: 1410-1416.
25. Juniper EF, Svensson K, Mörk AC, Ståhl E,. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respir Med 2005; 99: 553-558.
26. Wyrwich KW, Khan SA, Navaratnam P, Nolte H, Gates DF Jr,. Validation and agreement across four versions of the asthma control questionnaire in patients with persistent asthma. Respir Med 2011; 105: 698-712.
27. Beeh KM, Kanniess F, Wagner F, Schilder C, Naudts I, Hammann-Haenni A, et al. The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent allergic asthma. J Allergy Clin Immunol 2013; 131: 866-874.
28. Busse WW, Wenzel SE, Meltzer EO, Kerwin EM, Liu MC, Zhang N, et al. Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients. J Allergy Clin Immunol 2013; 131: 339-345.
29. Follows RM, Snowise NG, Ho SY, Ambery CL, Smart K, McQuade BA,. Efficacy, safety and tolerability of GSK2190915, a 5-lipoxygenase activating protein inhibitor, in adults and adolescents with persistent asthma: a randomised dose-ranging study. Respir Res 2013; 14: 54.
30. Piper E, Brightling C, Niven R, Oh C, Faggioni R, Poon K, et al. A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma. Eur Respir J 2013; 41: 330-338.
31. Short PM, Williamson PA, Anderson WJ, Lipworth BJ,. Randomized placebo-controlled trial to evaluate chronic dosing effects of propranolol in asthma. Am J Respir Crit Care Med 2013; 187: 1308-1314.
32. Nair P, Gaga M, Zervas E, Alagha K, Hargreave FE, O'Byrne PM, et al. Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical trial. Clin Exp Allergy 2012; 42: 1097-1103.
33. Wasfi YS, Villarán C, de Tilleghem Cle B, Smugar SS, Hanley WD, Reiss TF, et al. The efficacy and tolerability of MK-0633, a 5-lipoxygenase inhibitor, in chronic asthma. Respir Med 2012; 106: 34-46.
34. Castro M, Mathur S, Hargreave F, Boulet LP, Xie F, Young J, et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med 2011; 184: 1125-1132.
35. Holgate ST, Noonan M, Chanez P, Busse W, Dupont L, Pavord I, et al. Efficacy and safety of etanercept in moderate-to-severe asthma: a randomised, controlled trial. Eur Respir J 2011; 37: 1352-1359.
36. Ma J, Strub P, Camargo CA Jr, Xiao L, Ayala E, Gardner CD, et al. The Breathe Easier through Weight Loss Lifestyle (BE WELL) Intervention: a randomized controlled trial. BMC Pulm Med 2010; 10: 16.
37. Kazaks AG, Uriu-Adams JY, Albertson TE, Shenoy SF, Stern JS,. Effect of oral magnesium supplementation on measures of airway resistance and subjective assessment of asthma control and quality of life in men and women with mild to moderate asthma: a randomized placebo controlled trial. J Asthma 2010; 47: 83-92.
38. Corren J, Busse W, Meltzer EO, Mansfield L, Bensch G, Fahrenholz J, et al. A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma. Am J Respir Crit Care Med 2010; 181: 788-796.
39. Humbert M, de Blay F, Garcia G, Prud'homme A, Leroyer C, Magnan A, et al. Masitinib, a c-kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid-dependent asthmatics. Allergy 2009; 64: 1194-1201.
40. Thomas M, Sheran J, Smith N, Fonseca S, Lee AJ,. AKL1, a botanical mixture for the treatment of asthma: a randomised, double-blind, placebo-controlled, cross-over study. BMC Pulm Med 2007; 7: 4.
41. Lang JE, Mougey EB, Allayee H, Blake KV, Lockey R, Gong Y, et al. Nutrigenetic response to omega-3 fatty acids in obese asthmatics (NOOA): rationale and methods. Contemp Clin Trials 2013; 34: 326-335.
42. Spears M, Donnelly I, Jolly L, Brannigan M, Ito K, McSharry C, et al. Effect of low-dose theophylline plus beclometasone on lung function in smokers with asthma: a pilot study. Eur Respir J 2009; 33: 1010-1017.
43. Kerstjens HA, Engel M, Dahl R, Paggiaro P, Beck E, Vandewalker M, et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med 2012; 367: 1198-1207.
44. Lin JT, Chen P, Zhou X, Sun TY, Xie CM, Xiu QY, et al. Budesonide/formoterol maintenance and reliever therapy in Chinese patients with asthma. Chin Med J (Engl) 2012; 125: 2994-3001.
45. Riemersma RA, Postma D, van der Molen T,. Budesonide/formoterol maintenance and reliever therapy in primary care asthma management: effects on bronchial hyperresponsiveness and asthma control. Prim Care Respir J 2012; 21: 50-56.
46. O'Connor RD, Patrick DL, Parasuraman B, Martin P, Goldman M,. Comparison of patient-reported outcomes during treatment with adjustable- and fixed-dose budesonide/formoterol pressurized metered-dose inhaler versus fixed-dose fluticasone propionate/salmeterol dry powder inhaler in patients with asthma. J Asthma 2010; 47: 217-223.
47. Sutherland ER, King TS, Icitovic N, Ameredes BT, Bleecker E, Boushey HA, et al. A trial of clarithromycin for the treatment of suboptimally controlled asthma. J Allergy Clin Immunol 2010; 126: 747-753.
48. FitzGerald JM, Foucart S, Coyle S, Sampalis J, Haine D, Psaradellis E, et al. Montelukast as add-on therapy to inhaled corticosteroids in the management of asthma (the SAS trial). Can Respir J 2009; 16 (Suppl A): 5A-14A.
49. Louis R, Joos G, Michils A, Vandenhoven G,. A comparison of budesonide/formoterol maintenance and reliever therapy vs. conventional best practice in asthma management. Int J Clin Pract 2009; 63: 1479-1488.
50. Barnes N, van Noord JA, Brindicci C, Lindemann L, Varoli G, Perpiña M, et al. Stepping-Across controlled asthmatic patients to extrafine beclometasone/formoterol combination. Pulm Pharmacol Ther 2013; 26: 555-561.
51. Brusselle GG, Vanderstichele C, Jordens P, Deman R, Slabbynck H, Ringoet V, et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax 2013; 68: 322-329.
52. Anderson WJ, Short PM, Williamson PA, Lipworth BJ,. Inhaled corticosteroid dose response using domiciliary exhaled nitric oxide in persistent asthma: the FENOtype trial. Chest 2012; 142: 1553-1561.
53. Brown ES, Howard C, Khan DA, Carmody TJ,. Escitalopram for severe asthma and major depressive disorder: a randomized, double-blind, placebo-controlled proof-of-concept study. Psychosomatics 2012; 53: 75-80.
54. Brusselle G, Peché R, Van den Brande P, Verhulst A, Hollanders W, Bruhwyler J,. Real-life effectiveness of extrafine beclometasone dipropionate/formoterol in adults with persistent asthma according to smoking status. Respir Med 2012; 106: 811-819.
55. Writing Committee for the American Lung Association Asthma Clinical Research Centers, Holbrook JT, Wise RA, Gold BD, Blake K, Brown ED, et al. Lansoprazole for children with poorly controlled asthma: a randomized controlled trial. JAMA 2012; 307: 373-381.
56. Manap RA, Loh LC, Ismail TS, Muttalif AR, Simon GK, Toh RB, et al. Satisfaction levels and asthma control amongst Malaysian asthmatic patients on budesonide/formoterol maintenance and reliever therapy: experience in a real-life setting. Patient Relat Outcome Meas 2012; 3: 71-78.
57. Bousquet J, Siergiejko Z, Swiebocka E, Humbert M, Rabe KF, Smith N, et al. Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma. Allergy 2011; 66: 671-678.
58. Clerisme-Beaty EM, Bartlett SJ, Teague WG, Lima J, Irvin CG, Cohen R, et al. The Madison Avenue effect: how drug presentation style influences adherence and outcome in patients with asthma. J Allergy Clin Immunol 2011; 127: 406-411.
59. Keith PK, Koch C, Djandji M, Bouchard J, Psaradellis E, Sampalis JS, et al. Montelukast as add-on therapy with inhaled corticosteroids alone or inhaled corticosteroids and long-Acting beta-2-Agonists in the management of patients diagnosed with asthma and concurrent allergic rhinitis (the RADAR trial). Can Respir J 2009; 16 (Suppl A): 17A-31A.
60. McIvor RA, Kaplan A, Koch C, Sampalis JS,. Montelukast as an alternative to low-dose inhaled corticosteroids in the management of mild asthma (the SIMPLE trial): an open-label effectiveness trial. Can Respir J 2009; 16 (Suppl A): 11A-21A.
61. Brown ES, Vigil L, Khan DA, Liggin JD, Carmody TJ, Rush AJ,. A randomized trial of citalopram versus placebo in outpatients with asthma and major depressive disorder: a proof of concept study. Biol Psychiatry 2005; 58: 865-870.
62. Molimard M, Martinat Y, Rogeaux Y, Moyse D, Pello JY, Giraud V,. Improvement of asthma control with beclomethasone extrafine aerosol compared to fluticasone and budesonide. Respir Med 2005; 99: 770-778.
63. Akamatsu T, Shirai T, Kato M, Yasui H, Hashimoto D, Fujisawa T, et al. Switching from salmeterol/fluticasone to formoterol/budesonide combinations improves peripheral airway/alveolar inflammation in asthma. Pulm Pharmacol Ther 2014; 27: 52-56.
64. Ayars AG, Altman LC, Potter-Perigo S, Radford K, Wight TN, Nair P,. Sputum hyaluronan and versican in severe eosinophilic asthma. Int Arch Allergy Immunol 2013; 161: 65-73.
65. Baptist AP, Ross JA, Yang Y, Song PX, Clark NM,. A randomized controlled trial of a self-regulation intervention for older adults with asthma. J Am Geriatr Soc 2013; 61: 747-753.
66. Correia de Sousa J, Pina A, Cruz AM, Quelhas A, Almada-Lobo F, Cabrita J, et al. Asthma control, quality of life, and the role of patient enablement: a cross-sectional observational study. Prim Care Respir J 2013; 22: 181-187.
67. Honkoop PJ, Loijmans RJ, Termeer EH, Snoeck-Stroband JB, Ter Riet G, Schermer TR, et al. Comparison between an online self-Administered and an interviewer-Administered version of the Asthma Control Questionnaire: a cross-sectional validation study. Prim Care Respir J 2013; 22: 284-289.
68. Mancuso CA, Choi TN, Westermann H, Wenderoth S, Wells MT, Charlson ME,. Improvement in asthma quality of life in patients enrolled in a prospective study to increase lifestyle physical activity. J Asthma 2013; 50: 103-107.
69. Obase Y, Ikeda M, Kurose K, Abe M, Shimizu H, Ohue Y, et al. Step-down of budesonide/formoterol in early stages of asthma treatment leads to insufficient anti-inflammatory effect. J Asthma 2013; 50: 718-721.
70. Akamatsu T, Shirai T, Kato M, Hashimoto D, Yasui H, Inui N, et al. Effect of switching from salmeterol/fluticasone to formoterol/ budesonide combinations in patients with uncontrolled asthma. Allergol Int 2012; 61: 323-329.
71. Kersten ET, van Leeuwen JC, Brand PL, Duiverman EJ, de Jongh FH, Thio BJ, et al. Effect of an intranasal corticosteroid on exercise induced bronchoconstriction in asthmatic children. Pediatr Pulmonol 2012; 47: 27-35.
72. Rijssenbeek-Nouwens LH, Fieten KB, Bron AO, Hashimoto S, Bel EH, Weersink EJ,. High-Altitude treatment in atopic and nonatopic patients with severe asthma. Eur Respir J 2012; 40: 1374-1380.
73. Ryan D, Price D, Musgrave SD, Malhotra S, Lee AJ, Ayansina D, et al. Clinical and cost effectiveness of mobile phone supported self monitoring of asthma: multicentre randomised controlled trial. BMJ 2012; 344: e1756.
74. Schumann C, Kropf C, Wibmer T, Rüdiger S, Stoiber KM, Thielen A, et al. Omalizumab in patients with severe asthma: the XCLUSIVE study. Clin Respir J 2012; 6: 215-227.
75. van Schayck OC, Haughney J, Aubier M, Selroos O, Ekström T, Ostinelli J, et al. Do asthmatic smokers benefit as much as non-smokers on budesonide/formoterol maintenance and reliever therapy? Results of an open label study. Respir Med 2012; 106: 189-196.
76. Aubier M, Haughney J, Selroos O, van Schayck OC, Ekström T, Ostinelli J, et al. Is the patient's baseline inhaled steroid dose a factor for choosing the budesonide/formoterol maintenance and reliever therapy regimen? Ther Adv Respir Dis 2011; 5: 289-298.
77. Barros R, Moreira A, Fonseca J, Delgado L, Castel-Branco MG, Haahtela T, et al. Dietary intake of alpha-linolenic acid and low ratio of n-6:n-3 PUFA are associated with decreased exhaled NO and improved asthma control. Br J Nutr 2011; 106: 441-450.
78. Dogra S, Kuk JL, Baker J, Jamnik V,. Exercise is associated with improved asthma control in adults. Eur Respir J 2011; 37: 318-323.
79. Haughney J, Aubier M, Jørgensen L, Ostinelli J, Selroos O, van Schayck CP, et al. Comparing asthma treatment in elderly versus younger patients. Respir Med 2011; 105: 838-845.
80. Hozawa S, Terada M, Hozawa M,. Comparison of budesonide/formoterol Turbuhaler with fluticasone/salmeterol Diskus for treatment effects on small airway impairment and airway inflammation in patients with asthma. Pulm Pharmacol Ther 2011; 24: 571-576.
81. Price D, Musgrave SD, Shepstone L, Hillyer EV, Sims EJ, Gilbert RF, et al. Leukotriene antagonists as first-line or add-on asthma-controller therapy. N Engl J Med 2011; 364: 1695-1707.
82. Quirce S, Barcina C, Plaza V, Calvo E, Muñoz M, Ampudia R, et al. A comparison of budesonide/formoterol maintenance and reliever therapy versus conventional best practice in asthma management in Spain. J Asthma 2011; 48: 839-847.
83. Søes-Petersen U, Kava T, Dahle R, Lei Y, Dam N,. Budesonide/formoterol maintenance and reliever therapy versus conventional best standard treatment in asthma in an attempted 'real life' setting. Clin Respir J 2011; 5: 173-182.
84. Yamada S, Kuwahara H, Asai R, Kotani H, Kishi R, Hirabayashi A, et al. [Evaluation of the symptoms, adherence and satisfaction after pharmaceutical care at asthma clinic for outpatient]. Yakugaku Zasshi 2012; 131: 1629-1638.
85. Zapatero L, Martínez-Cañavate A, Lucas JM, Guallar I, Torres J, Guardia P, et al. Clinical evolution of patients with respiratory allergic disease due to sensitisation to Alternaria alternata being treated with subcutaneous immunotherapy. Allergol Immunopathol (Madr) 2011; 39: 79-84.
86. Boulet LP, Deschesnes F, Chaboillez S, Lemière C,. Protocol: influence of budesonide and budesonide/formoterol on asthma control in smoking asthmatic adults. Open Respir Med J 2010; 4: 51-57.
87. Brown ES, Denniston D, Gabrielson B, Khan DA, Khanani S, Desai S,. Randomized, double-blind, placebo-controlled trial of acetaminophen for preventing mood and memory effects of prednisone bursts. Allergy Asthma Proc 2010; 31: 331-336.
88. Cowan DC, Cowan JO, Palmay R, Williamson A, Taylor DR,. Simvastatin in the treatment of asthma: lack of steroid-sparing effect. Thorax 2010; 65: 891-896.
89. Reddel HK, Gibson PG, Peters MJ, Wark PA, Sand IB, Hoyos CM, et al. Down-titration from high-dose combination therapy in asthma: removal of long-Acting beta(2)-Agonist. Respir Med 2010; 104: 1110-1120.
90. Schlick W, Pohl W, Pfeiffer KP, Aigner K, Forche G, Kneussl M, et al. Evaluation of 3-5 months' add-on therapy with montelukast in patients with non-controlled asthma in Austria: the STAR open-label, real-world, observational study. Curr Med Res Opin 2010; 26: 561-570.
91. van der Meer V, van Stel HF, Bakker MJ, Roldaan AC, Assendelft WJ, Sterk PJ, et al. Weekly self-monitoring and treatment adjustment benefit patients with partly controlled and uncontrolled asthma: an analysis of the SMASHING study. Respir Res 2010; 11: 74.
92. Wenzel SE, Robinson CB, Leonard JM, Panettieri RA Jr,. Nebulized dehydroepiandrosterone-3-sulfate improves asthma control in the moderate-to-severe asthma results of a 6-week, randomized, double-blind, placebo-controlled study. Allergy Asthma Proc 2010; 31: 461-471.
93. Wilson EC, Price D, Musgrave SD, Sims EJ, Shepstone L, Murdoch J, et al. Cost effectiveness of leukotriene receptor antagonists versus long-Acting beta-2 agonists as add-on therapy to inhaled corticosteroids for asthma: a pragmatic trial. Pharmacoeconomics 2010; 28: 597-608.
94. Wilson EC, Sims EJ, Musgrave SD, Shepstone L, Blyth A, Murdoch J, et al. Cost effectiveness of leukotriene receptor antagonists versus inhaled corticosteroids for initial asthma controller therapy: a pragmatic trial. Pharmacoeconomics 2010; 28: 585-595.
95. Goossens LM, Riemersma RA, Postma DS, van der Molen T, Rutten-van Mölken MP,. An economic evaluation of budesonide/formoterol for maintenance and reliever treatment in asthma in general practice. Adv Ther 2009; 26: 872-885.
96. Kerwin EM, Oppenheimer JJ, LaForce C, Parasuraman B, Miller CJ, O'Dowd L, et al. Efficacy and tolerability of once-daily budesonide/formoterol pressurized metered-dose inhaler in adults and adolescents with asthma previously stable with twice-daily budesonide/ formoterol dosing. Ann Allergy Asthma Immunol 2009; 103: 62-72.
97. Kopp MV, Hamelmann E, Zielen S, Kamin W, Bergmann KC, Sieder C, et al. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma. Clin Exp Allergy 2009; 39: 271-279.
98. Korn D, Van den Brande P, Potvin E, Dramaix M, Herbots E, Peché R,. Efficacy of add-on montelukast in patients with non-controlled asthma: a Belgian open-label study. Curr Med Res Opin 2009; 25: 489-497.
99. Lindemann J, David Pampe E, Peterkin JJ, Orozco-Cronin P, Belofsky G, Stull D,. Clinical study of the effects on asthma-related QOL and asthma management of a medical food in adult asthma patients. Curr Med Res Opin 2009; 25: 2865-2875.
100. Pacheco-Galván A, Hinojosa-Macías M, Hurtado-Barbudo B, González-Cervera J, Sueiro-Bendito A,. Analysis of asthma control and quality of life in severe allergic asthmatics under treatment with anti-IgE, omalizumab. Med Clin (Barc) 2009; 133: 460-463.
101. Thomas M, McKinley RK, Mellor S, Watkin G, Holloway E, Scullion J, et al. Breathing exercises for asthma: a randomised controlled trial. Thorax 2009; 64: 55-61.
102. Mastronarde JG, Wise RA, Shade DM, Olopade CO, Scharf SM, American Lung Association Asthma Clinical Research Centers. Sleep quality in asthma: results of a large prospective clinical trial. J Asthma 2008; 45: 183-189.
103. Morjaria JB, Chauhan AJ, Babu KS, Polosa R, Davies DE, Holgate ST,. The role of a soluble TNFalpha receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double blind, randomised, placebo controlled trial. Thorax 2008; 63: 584-591.
104. Surette ME, Stull D, Lindemann J,. The impact of a medical food containing gammalinolenic and eicosapentaenoic acids on asthma management and the quality of life of adult asthma patients. Curr Med Res Opin 2008; 24: 559-567.
105. Cleland JA, Hall S, Price D, Lee AJ,. An exploratory, pragmatic, cluster randomised trial of practice nurse training in the use of asthma action plans. Prim Care Respir J 2007; 16: 311-318.
106. Cox G, Thomson NC, Rubin AS, Niven RM, Corris PA, Siersted HC, et al. Asthma control during the year after bronchial thermoplasty. N Engl J Med 2007; 356: 1327-1337.
107. Deykin A, Wechsler ME, Boushey HA, Chinchilli VM, Kunselman SJ, Craig TJ, et al. Combination therapy with a long-Acting beta-Agonist and a leukotriene antagonist in moderate asthma. Am J Respir Crit Care Med 2007; 175: 228-234.
108. Pavord ID, Cox G, Thomson NC, Rubin AS, Corris PA, Niven RM, et al. Safety and efficacy of bronchial thermoplasty in symptomatic, severe asthma. Am J Respir Crit Care Med 2007; 176: 1185-1191.
109. Lundborg M, Wille S, Bjermer L, Tilling B, Lundgren M, Telg G, et al. Maintenance plus reliever budesonide/formoterol compared with a higher maintenance dose of budesonide/formoterol plus formoterol as reliever in asthma: an efficacy and cost-effectiveness study. Curr Med Res Opin 2006; 22: 809-821.
110. Reti S,. Ventolin to Salamol-A crossover study in New Zealand. N Z Med J 2006; 119: U2276.
111. Shimizu Y, Dobashi K, Kobayashi S, Ohki I, Tokushima M, Kusano M, et al. A proton pump inhibitor, lansoprazole, ameliorates asthma symptoms in asthmatic patients with gastroesophageal reflux disease. Tohoku J Exp Med 2006; 209: 181-189.
112. Zeiger RS, Szefler SJ, Phillips BR, Schatz M, Martinez FD, Chinchilli VM, et al. Response profiles to fluticasone and montelukast in mild-to-moderate persistent childhood asthma. J Allergy Clin Immunol 2006; 117: 45-52.
113. Gruffydd-Jones K, Hollinghurst S, Ward S, Taylor G,. Targeted routine asthma care in general practice using telephone triage. Br J Gen Pract 2005; 55: 918-923.
114. Rosenhall L, Elvstrand A, Tilling B, Vinge I, Jemsby P, Ståhl E, et al. One-year safety and efficacy of budesonide/formoterol in a single inhaler (Symbicort Turbuhaler) for the treatment of asthma. Respir Med 2003; 97: 702-708.
115. Busse WW, Holgate S, Kerwin E, Chon Y, Feng J, Lin J, et al. Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. Am J Respir Crit Care Med 2013; 188: 1294-1302.
116. Schatz M, Sorkness CA, Li JT, Marcus P, Murray JJ, Nathan RA, et al. Asthma Control Test: reliability, validity, and responsiveness in patients not previously followed by asthma specialists. J Allergy Clin Immunol 2006; 117: 549-556.
117. Boulet LP, Boulet V, Milot J,. How should we quantify asthma control? A proposal. Chest 2002; 122: 2217-2223.
118. Vollmer WM, Markson LE, O'Connor E, Frazier EA, Berger M, Buist AS,. Association of asthma control with health care utilization: a prospective evaluation. Am J Respir Crit Care Med 2002; 165: 195-199.
119. Wood PR, Smith B, O'Donnell L, Galbreath AD, Lara M, Forkner E, et al. Quantifying asthma symptoms in adults: the Lara Asthma Symptom Scale. J Allergy Clin Immunol 2007; 120: 1368-1372.
120. Kiotseridis H, Bjermer L, Pilman E, Ställberg B, Romberg K, Tunsäter A,. ALMA, a new tool for the management of asthma patients in clinical practice: development, validation and initial clinical findings. Prim Care Respir J 2012; 21: 139-144.
121. Juniper EF, Guyatt GH, Epstein RS, Ferrie PJ, Jaeschke R, Hiller TK,. Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax 1992; 47: 76-83.
122. Jia CE, Zhang HP, Lv Y, Liang R, Jiang YQ, Powell H, et al. The Asthma Control Test and Asthma Control Questionnaire for assessing asthma control: systematic review and meta-Analysis. J Allergy Clin Immunol 2013; 131: 695-703.
123. Almeida PC, Souza-Machado A, Leite Mdos S, Castro LA, Coelho AC, Cruz CS, et al. Comparison between two methods of asthma control evaluation based on individual perception. J Bras Pneumol 2012; 38: 299-307.
124. Bime C, Wei CY, Holbrook JT, Sockrider MM, Revicki DA, Wise RA,. Asthma symptom utility index: reliability, validity, responsiveness, and the minimal important difference in adult asthmatic patients. J Allergy Clin Immunol 2012; 130: 1078-1084.
125. Crane MA, Douglass JA, Goeman DP, Cousens NE, Jenkins CR,. Development and validation of the Patient Asthma Concerns Tool (PACT) to identify the needs of older people with asthma. Respir Med 2012; 106: 1501-1508.
126. Korn S, Both J, Jung M, Hübner M, Taube C, Buhl R,. Prospective evaluation of current asthma control using ACQ and ACT compared with GINA criteria. Ann Allergy Asthma Immunol 2011; 107: 474-479.
127. Madhuban AA, Driessen JM, Brusse-Keizer MG, van Aalderen WM, de Jongh FH, Thio BJ,. Association of the asthma control questionnaire with exercise-induced bronchoconstriction. J Asthma 2011; 48: 275-278.
128. Fonseca JA, Nogueira-Silva L, Morais-Almeida M, Azevedo L, Sa-Sousa A, Branco-Ferreira M, et al. Validation of a questionnaire (CARAT10) to assess rhinitis and asthma in patients with asthma. Allergy 2010; 65: 1042-1048.
129. Zhou X, Ding FM, Lin JT, Yin KS,. Validity of asthma control test for asthma control assessment in Chinese primary care settings. Chest 2009; 135: 904-910.
130. Wallenstein GV, Carranza-Rosenzweig J, Kosinski M, Blaisdell-Gross B, Gajria K, Jhingran P,. A psychometric comparison of three patient-based measures of asthma control. Curr Med Res Opin 2007; 23: 369-377.
131. Zhou X, Ding FM, Lin JT, Yin KS, Chen P, He QY, et al. Validity of Asthma Control Test in Chinese patients. Chin Med J (Engl) 2007; 120: 1037-1041.
132. Ehrs PO, Nokela M, Ställberg B, Hjemdahl P, Wikström Jonsson E,. Brief questionnaires for patient-reported outcomes in asthma: validation and usefulness in a primary care setting. Chest 2006; 129: 925-932.
133. van den Nieuwenhof L, Schermer T, Eysink P, Halet E, van Weel C, Bindels P, et al. Can the Asthma Control Questionnaire be used to differentiate between patients with controlled and uncontrolled asthma symptoms? A pilot study. Fam Pract 2006; 23: 674-681.
134. US Department of Health and Human Services FDA Center for Drug Evaluation and Research; US Department of Health and Human Services FDA Center for Biologics Evaluation and Research; US Department of Health and Human Services FDA Center for Devices and Radiological Health. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes 2006; 4: 79.
135. Juniper EF, Bousquet J, Abetz L, Bateman ED,; GOAL Committee. Identifying 'well-controlled' and 'not well-controlled' asthma using the Asthma Control Questionnaire. Respir Med 2006; 100: 616-621.
136. Schatz M, Kosinski M, Yarlas AS, Hanlon J, Watson ME, Jhingran P,. The minimally important difference of the Asthma Control Test. J Allergy Clin Immunol 2009; 124: 719-723.
137. Cloutier MM, Schatz M, Castro M, Clark N, Kelly HW, Mangione-Smith R, et al. Asthma outcomes: composite scores of asthma control. J Allergy Clin Immunol 2012; 129 (Suppl 3): S24-S33.
138. Meltzer EO, Busse WW, Wenzel SE, Belozeroff V, Weng HH, Feng J, et al. Use of the Asthma Control Questionnaire to predict future risk of asthma exacerbation. J Allergy Clin Immunol 2011; 127: 167-172.
139. Liu AH, Zeiger R, Sorkness C, Mahr T, Ostrom N, Burgess S, et al. Development and cross-sectional validation of the Childhood Asthma Control Test. J Allergy Clin Immunol 2007; 119: 817-825.